# Study of the Safety and Efficacy of the Subunit Recombinant Tuberculosis Vaccine GamTBvac

> **NCT04975737** · PHASE3 · UNKNOWN · sponsor: **Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation** · enrollment: 7180 (estimated)

## Conditions studied

- Tuberculosis

## Interventions

- **BIOLOGICAL:** GamTBvac
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT04975737
- **Lead sponsor:** Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-20
- **Primary completion:** 2025-11
- **Final completion:** 2025-11
- **Target enrollment:** 7180 (ESTIMATED)
- **Last updated:** 2022-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04975737

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04975737, "Study of the Safety and Efficacy of the Subunit Recombinant Tuberculosis Vaccine GamTBvac". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT04975737. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*